15 results about "Epicatechin gallate" patented technology

Described herein are methods of treating a human child including administering to the human child a compound selected from epigallocatechin gallate (EGCG), or a derivative thereof selected from epicatechin (EC), epigallocatechin (RGC) and epicatechin gallate (ECG), sulforaphane, olive oil, phylloquinone, quercetin, safranal, hydroxtyrosol, menaquinone-4, menaquinone-7, oleocanthal, peptide Ins-1 B9-23 19CAM22R-E, peptide Ins-1 B12-23-19CAM, peptide Ins-1 B12-23 19CAM22R-E, or a combination of any of the foregoing, wherein administration of the treatment is started between birth and six months of age. Also described are methods of treating a pregnant human or a nursing human mother who has recently given birth to an infant. Further described are insulin B chain mimotope peptides.

The invention provides a preparation process of a soothing and repairing type mask, and belongs to the technical field of cosmetics, an intelligent response type cell bionic delivery system is adopted, macrophage membrane vesicles serve as a carrier, a composite repairing kernel, epicatechin gallate, a neuropeptide P substance antagonist and idebenone are wrapped, and by means of the inflammation chemotaxis of a macrophage membrane, the soothing and repairing type mask is prepared. According to the present invention, the active component can actively target the inflammation region, the phase change release core is provided in the weakly acidic microenvironment with the pH value of 5.0-6.0, the targeting property and the permeation efficiency of the active component can be improved, the bottleneck of the traditional passive diffusion can be broken through, and compared with the conventional liposome or nanoparticle, the active component can be accurately delivered to the inflammation core region, the permeation rate can be improved by several times, and the carrier can directly reach the problem core region; according to the method, the utilization rate of effective components is greatly increased, a micro-ecology-immunity-nerve-physical barrier multi-dimensional and systematic synergistic repair network is constructed, full-path fundamental repair from immediate relieving to root strengthening is achieved, and immediate relieving and long-term barrier repair effects are provided.

Nutritional supplements and compositions for activating cellular signaling genes in innate inflammatory pathways are described in this application. In particular, this application describes a composition containing a solid portion comprising Bacopa monnieri extract having a least 20 percent bacosides, Silybum marianum (milk thistle) extract having 70 percent to about 80 percent silymarin, milk thistle extract, Withania somnifera (ashwagandha) extract, Camellia sinensis (green tea) extract containing at least 40 percent epigallocatechin gallate and about 98 percent polyphenols; and Curcuma longa (turmeric) extract containing at least about 95 percent curcumin. The compositions also comprise a liquid portion comprising fish collagen peptides comprising about 90 percent protein and Formosa ruby quinoa water extract containing about 10 wt % extract and about 90 wt % water. These compositions improved the skin and impacted key regulatory genes associated with several important cellular pathways. Other embodiments are also described.

The application discloses an EPA liposome and a preparation method and application thereof, and particularly relates to the technical field of cosmetics. The EPA liposome is prepared through self-assembly of liposomes by using the following raw materials in parts by mass: microalgae oil EPA 1-4 parts, epicatechin-3-gallate 1-2 parts, alpha-tocopherol 0.2-1 part, ginsenoside Rg3 0.02-0.1 part, lipids 2-10 parts, emulsifier 1-10 parts, and water is supplemented to 100 parts. The EPA liposome realizes the stable effect of EPA in a composite system such as a cosmetic skin care product, enhances the in-situ antioxidant and protective functions of EPA and slows down the autoxidation of EPA, improves the bioavailability and enhances the anti-aging effect through the synergy of the contained efficacy substances and the design of the nano-liposome.

The invention discloses a preparation method and application of hempseed (-)-epicatechin-3-O-gallate, and belongs to the technical field of biology. According to the preparation method disclosed by the invention, the non-ester catechin and the ester-rich catechin are separated by adopting the mixed solvents of the ethanol, the methanol and the isopropanol, so that the extraction rate of the (-)-epicatechin-3-O-gallate can be improved (97% or above). Meanwhile, recrystallization is carried out by adopting organic solvents of methanol, normal propyl alcohol and isopropyl alcohol after extraction, so that the purity of the hempseed (-)-epicatechin-3-O-gallate can be improved (98% or above). The extracted epicatechin-3-O-gallate (ECG) is a natural antioxidant, has good biological activity, and has a good treatment effect on prevention and treatment of the hyperuricemia nephropathy.

Described herein are compositions (e.g., topical formulations) including andrographolides (ANGL), epigallocatechin gallate (EGCG), or a combination thereof, and methods of making and using the same.

This invention relates to the field of pharmaceutical technology, specifically to the application of dehydronuciolin and fluconazole in the preparation of antifungal drugs. The in vitro synergistic effect of the combination of dehydronuciolin and fluconazole was determined using a checkerboard assay, showing a fractional inhibitory concentration (FIC) ≤0.5, confirming a strong synergistic effect. The in vivo efficacy of this drug combination was verified using a large wax moth infection model. Phenotypic experiments explored the synergistic mechanism, showing that the combination of dehydronuciolin and fluconazole significantly inhibited the hyphal growth, biofilm formation, and adhesion to host cells of drug-resistant Candida albicans. Transcriptome sequencing analysis confirmed these findings, showing that treatment with the combination of dehydronuciolin and fluconazole downregulated hyphae-specific genes, GPI-anchored cell wall proteins, and the ergosterol biosynthesis pathway, collectively weakening the virulence, surface integrity, and host recognition ability of Candida albicans, thereby reversing its drug resistance.

There has been need for tea beverages that maintain characteristics thereof while maintaining drinkability even with a low pH. One aspect of the present invention provides a beverage containing diacetyl and catechins, wherein the diacetyl content is at least 20 ppb and less than 10,000 ppb, the contained amount one or more types of catechins selected from epicatechin, catechin, epigallocatechin, gallocatechin, epicatechin gallate, catechin gallate, epigallocatechin gallate, and gallocatechin gallate is at least 1 ppm and less than 500 ppm, and the pH is 5 or lower.

This invention discloses a drug for viral myocarditis, relating to the field of drug preparation technology. The drug comprises at least one of imperatorin, isochorin, and epicatechin gallate. This drug can effectively inhibit viral replication in myocardial tissue, significantly reduce serum pro-inflammatory factor levels, alleviate inflammatory infiltration, and significantly reduce cell apoptosis, thereby exerting a therapeutic effect on viral myocarditis. This invention solves the problem of the lack of highly effective multi-target viral myocarditis drugs in the prior art.

This invention provides a method for synthesizing novel natural pigments using phenotypic catechins. Various epicatechins, epigallocatechins, epicatechin gallate esters, and epigallocatechin gallate esters are used as substrates. These are mixed and subjected to a non-enzymatic oxidation reaction under humid and hot conditions to generate a new class of tea pigment compounds. The non-enzymatic oxidation products of the phenotypic catechins are then concentrated under reduced pressure, freeze-dried, extracted, and purified by column chromatography to obtain dimeric catechin pigments. The six novel dimeric catechin pigments obtained by this invention are synthesized using a simple method. The six novel dimeric catechin pigments obtained according to the method of this invention are orange-yellow or orange-red amorphous powders with good color-adjusting capabilities, and can be applied to coloring tea beverages and new-style tea drinks. The discovery of this type of natural pigment contributes to the research on coloring substances during the thermal processing of tea, the improvement of tea liquor color quality, and the development and application in the field of food coloring.

This invention provides a novel method for producing bioactive high-molecular-weight polyphenols from fermented tea. [Solution] In reverse-phase high-performance liquid chromatography performed on an extract of fermented tea under conditions in which polyphenols and caffeine are separated and eluted, a group of compounds derived from the portion of the broad peak detected that has a longer retention time than the point at which epicatechin gallate is detected is purified from the water or water-containing organic solvent extract of the fermented tea using preparative chromatography, etc., which uses at least an aqueous solution containing an alcohol with 1 to 2 carbon atoms as the eluent, thereby obtaining the high molecular weight polyphenols. This makes it possible to produce a functional agent selected from the group consisting of a mitochondrial activator, a blood glucose level elevation inhibitor, an inhibitor of the formation of abnormal prion proteins, and a preventive and / or therapeutic agent for fatty liver.

A percutaneous absorption preparation for the treatment of dementia wherein the drug-containing layer contains donepezil or a pharmaceutically acceptable salt thereof as an active ingredient and a stabilizer that is either (i) a mixture of a thiocyanate salt and a compound selected from the group consisting of tea catechin, (+)-catechin, epigallocatechin gallate, ascorbic acid, and isoascorbic acid, or (ii) a mixture of monothioglycerol and a compound selected from the group consisting of tea catechin, (+)-catechin, epigallocatechin gallate, and ascorbic acid is disclosed. The percutaneous absorption preparation meets the criteria of Procedure 1 and Procedure 2 of the U.S. Pharmacopoeia in short-term stress test (70° C. 48 hours storage), long-term accelerated test 1 (40° C. relative humidity 75% 1 month storage), and long-term accelerated test 2 (40° C. relative humidity 75% 3 months storage), and exhibits improved stability for long-term preservation.

The invention discloses a nano-drug for enhancing the transplantation curative effect of stem cell-derived retinal ganglion cells as well as a preparation method and application of the nano-drug. Lithium ions and epicatechin gallate are self-assembled to form a lithium-epicatechin gallate nano-drug; the lithium-epicatechin gallate nano-drug is stable in structure and has strong oxidation and mitochondrial protection effects, the lithium-epicatechin gallate nano-drug and the epicatechin gallate nano-drug have synergistic interaction in function, and the lithium-epicatechin gallate nano-drug not only has dual nerve protection advantages, but also can improve drug stability and treatment effect; furthermore, the lithium-epicatechin gallate nano-drug and the embryonic stem cell-derived ganglion cells are transplanted in a combined manner, so that the survival rate and the neurite protection of the nano-drug under the oxidative stress condition can be remarkably improved, and more effective neuroprotection and functional reconstruction are realized in treatment of retina degenerative diseases such as glaucoma and the like.

The invention discloses a chlorhexidine gluconate gargle and a production process thereof. The toothpaste is prepared from the following components in parts by weight: 0.5 to 2 parts of chlorhexidine gluconate, 0.1 to 0.5 part of epicatechin gallate, 1 to 3 parts of honeysuckle flower extract, 0.8 to 2.5 parts of herba taraxaci extract, 0.2 to 0.8 part of dipotassium glycyrrhizinate, 5 to 12 parts of glycerol, 3 to 8 parts of polyethylene glycol 400, 0.3 to 1 part of sodium citrate, 0.2 to 0.7 part of sodium dihydrogen phosphate, 0.1 to 0.4 part of xanthan gum, 0.05 to 0.2 part of disodium EDTA (Ethylene Diamine Tetraacetic Acid), 0.1 to 0.5 part of menthol and 0.05 to 0.3 part of stevioside. The total weight is 100 parts; according to the invention, chlorhexidine gluconate is used as a main antibacterial component, epicatechin gallate and honeysuckle and dandelion extracts are compounded, a multi-target antibacterial system is constructed, the antibacterial spectrum is widened, the antibacterial effect is enhanced, and the problem of limitation of single-component bacteriostasis is solved; the dipotassium glycyrrhizinate is added to effectively relieve the irritation of chlorhexidine gluconate, and glycerol and polyethylene glycol 400 cooperate to improve the taste and improve the use comfort of the product.

The present disclosure provides a pharmaceutical composition for treating and / or reducing a likelihood of developing arthritis. In some embodiments, the pharmaceutical composition comprises a therapeutically-effective amount of curcumin; a therapeutically-effective amount of carvacrol; a therapeutically-effective amount of epigallocatechin-3-gallate; a therapeutically-effective amount of oligomeric proanthocyanidins; a therapeutically-effective amount of piperine; and a pharmaceutically acceptable carrier.